<DOC>
	<DOCNO>NCT00050414</DOCNO>
	<brief_summary>The purpose study test safety effectiveness investigational chemotherapy agent patient advanced ovarian cancer .</brief_summary>
	<brief_title>A Study Trabectedin Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description>Patients enrol study study-specific entry criterion meet informed consent obtain . Patients required attend regular clinic visit receive study medication status monitor . Patients also require radiologic tumor assessment perform multiple time throughout study . A detailed explanation provide study physician ( Investigator ) conduct study . Trabectedin start dose 0.58 mg/m2 give patient intravenously ( i.v ) . 3-hour infusion every week 3 week ( Days 1 , 8 , 15 ) 4 week cycle via central venous catheter ( also refer `` central line '' tube ie , `` catheter '' place large vein ) . All patient receive dexamethasone 10 mg i.v . 30 minute prior trabectedin infusion . Patients may receive multiple cycle trabectedin absence disease progression .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Ovarian Diseases</mesh_term>
	<mesh_term>Genital Diseases , Female</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Adnexal Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<criteria>Diagnosis advance epithelial ovarian cancer Progression recurrence platinumcontaining regimen At least one measureable tumor lesion Adequate bone marrow , hepatic renal function Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Known hypersensitivity component i.v . formulation trabectedin dexamethasone Pregnant lactate woman Known metastasis ( spread ) cancer central nervous system History another neoplastic disease unless remission five year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Ovary</keyword>
	<keyword>Cancer</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>ET743</keyword>
	<keyword>Ecteinascidin 743</keyword>
	<keyword>Antineoplastic Agents , Alkylating</keyword>
	<keyword>Alkylating Agents</keyword>
</DOC>